in vivo– tag –
-
Bioneer Unveils BioSPHEER™: A 3D Cancer Model Revolutionizing Solid Tumor Drug Discovery
Bioneer Denmark Overview Bioneer has launched BioSPHEER™, an innovative in vitro 3D cancer platform designed to significantly enhance drug efficacy prediction for solid tumors. This platform generates high-fidelity tumor models by assemb... -
Ossiform Explores the Nuances of 3D Cell Culture: Structural Scaffolds and Hydrogels for Advanced Microphysiological Systems
Ossiform Denmark Overview Ossiform has conducted an in-depth analysis of porous structural scaffolds and elastic synthetic hydrogels, highlighting their distinct strengths and weaknesses as 3D cell culture platforms for microphysiologica... -
Focused Ultrasound BBB Opening Facilitates Limited LNP-modRNA Brain Delivery in Niemann-Pick Disease Type C Mouse Model but Fails to Induce Therapeutic Effect
bioRxiv Unknown Overview Efficient molecular therapeutic delivery to the central nervous system (CNS) remains a major barrier in neurogenetic disorders like Niemann-Pick Disease Type C (NPC). This preprint evaluated Focused ultrasound-me... -
CDMO Signal Ranks Lentiviral Vector (LVV) CDMOs: GMP Standards and Robust Assays Key for Selection
CDMO Signal USA Overview CDMO Signal published its ranking of Lentiviral Vector (LVV) CDMOs based on Signal Score. LVVs are critical in ex vivo gene therapies for engineering CAR-T cells and modifying hematopoietic stem cells, necessitat... -
Lonza Presents Optimization Strategies to Address Purity and Potency Challenges in In Vivo Lentiviral Vector Development for Cell and Gene Therapies
Biocompare Switzerland Overview Lonza outlined optimization strategies for lentiviral vector (LVV) development for in vivo delivery of cell and gene therapies. Key challenges in LVV development include achieving purity, complexity of val... -
New Market Pitch Evaluates Top Cell Therapy Startups Including Orca Bio, Cellares, and Kelonia: Differentiated by Clinical, Manufacturing, and Strategic Advancements
New Market Pitch USA Overview New Market Pitch selected ten leading cell therapy startups—Orca Bio, Kyverna, Cabaletta Bio, Cellares, Immatics, Iovance, Sana, Kelonia, Orna, and Dispatch Bio—evaluating their regulatory maturity, clinical... -
VIVEbiotech Reaches 15 In Vivo Lentiviral Vector Programs, Fortifying Gene Therapy Manufacturing Leadership
BioPharma BoardRoom スペイン Overview VIVEbiotech has significantly advanced its position in gene therapy manufacturing by adding its 15th in vivo lentiviral vector (LVV) therapeutic program. This milestone underscores the company's robu... -
ASCO 2026 Emphasizes ‘Less Is More’: In Vivo CAR-T and Minimally Invasive, Highly Efficient Cancer Therapies Take Center Stage
Everest Clinical Research USA Overview ASCO 2026 highlighted 'Less Is More' as a guiding principle for future cancer care, with significant attention on evolving CAR-T cell therapies, particularly in vivo CAR-T approaches that engineer i... -
Efficient Prime Editing In Vivo and In Vitro Demonstrated with Lipid Nanoparticles: High Efficacy, Low Off-Target Effects
PubMed International Overview Recent research reports the development of an optimized platform for prime editing using lipid nanoparticles (PE-LNP), demonstrating high gene editing efficiency in vivo. This LNP-based system offers a compe... -
VIVEbiotech Scales In Vivo Gene Therapy Portfolio to 15 Programs, Securing Key FDA Clinical Trial Approvals
PharmaSource スペイン Overview Spanish CDMO VIVEbiotech has significantly expanded its in vivo lentiviral vector gene therapy portfolio to 15 programs, several of which have already secured regulatory clearance for clinical trials, inclu...
